Whole-cell vaccine candidates induce a protective response against virulent Acinetobacter baumannii

Front Immunol. 2022 Sep 27:13:941010. doi: 10.3389/fimmu.2022.941010. eCollection 2022.

Abstract

Acinetobacter baumannii causes multi-system diseases in both nosocomial settings and a pre-disposed general population. The bacterium is not only desiccation-resistant but also notoriously resistant to multiple antibiotics and drugs of last resort including carbapenem, colistin, and sulbactam. The World Health Organization has categorized carbapenem-resistant A. baumannii at the top of its critical pathogen list in a bid to direct urgent countermeasure development. Several early-stage vaccines have shown a range of efficacies in healthy mice, but no vaccine candidates have advanced into clinical trials. Herein, we report our findings that both an ionizing γ-radiation-inactivated and a non-ionizing ultraviolet C-inactivated whole-cell vaccine candidate protects neutropenic mice from pulmonary challenge with virulent AB5075, a particularly pathogenic isolate. In addition, we demonstrate that a humoral response is sufficient for this protection via the passive immunization of neutropenic mice.

Keywords: A. baumannii; MDP; UVC; humoral; protection; pulmonary; vaccine; whole-cell.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acinetobacter Infections* / microbiology
  • Acinetobacter Infections* / prevention & control
  • Acinetobacter baumannii*
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use
  • Colistin / pharmacology
  • Colistin / therapeutic use
  • Humans
  • Mice
  • Sulbactam / pharmacology
  • Sulbactam / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Sulbactam
  • Colistin